Slide 1: External challenges remain but are expected to ease in 2023
External challenges remain but are expected to ease in 2023 Getinge Q4 2022 Mattias Perjos, CEO Lars Sandström, CFO
Slide 2: State of Healthcare: "Less for more"
State of Healthcare: ”Less for more” Healthcare spend through the roof … and output going down Demand increase • COVID quarantine weaker immune system more patients • Backlog of elective procedures Tougher cases • Staying away from hospitals during COVID diagnosed at a later and more severe st
Slide 3: Key takeaways
Key takeaways Q4 2022 • Net sales decreased by 5.3% and order intake decreased by 6.7% organically • Margins impacted by volume, mix, supply and inflation • Healthy Free Cash Flow and financial position remains strong • Proposed dividend 4.25 (4.00) SEK/share 28,292 55 25 50.8 20 15.1 25,000 50 15 0
Slide 4: Key activities and events
Key activities and events Q4 2022 Offering and customers IAC in the quarter amounting to SEK -437 M • Livit Flex – a new bioprocess control system for • SEK 195 M acquisition and restructuring costs increased effectiveness in drug development – will start to bring cost savings gradually in 2023 • UL
Slide 5: Last year's growth impacting Y-o-Y comparisons
Last year’s growth impacting Y-o-Y comparisons But order intake up in China in December as a consequence of COVID flare ups Global Americas EMEA APAC Organic Order Growth -6.7% Organic Net Sales Growth -5.3% Getinge │ Presentation │ Q4 Report 2022 February 1, 2023 Page 5
Slide 6: Net sales expected to grow 2-5% organically in 2023
Outlook 2023 Net sales expected to grow 2-5% organically in 2023 Getinge │ Presentation │ Q4 Report 2022 February 1, 2023 Page 6
Slide 7: Tough quarter on organic order growth – but it ended on a positive note
Tough quarter on organic order growth – but it ended on a positive note Order Intake Bridge Q4 2021 – Q4 2022 Organic change -4.4% -32.0% +3.2% -6.7% +5.1% 361 346 -317 8,019 7,629 MSEK Q4 2021 Acute Care Therapies Life Science Surgical Workflows Q4 2022 Getinge │ Presentation │ Q4 Report 2022 Febru
Slide 8: Net sales negatively impacted by >400 MSEK due to supply issues in Q4
Net sales negatively impacted by >400 MSEK due to supply issues in Q4 Net Sales Bridge Q4 2021 – Q4 2022 Organic change -9.8% -3.6% +0.9% -5.3% +6.4% MSEK 131 81 299 911 Currency impact, MSEK 8,498 Organic growth, % 7,987 -4.9 Q4 2021 Acute Care Life Science Surgical Q4 2022 -5.8 Therapies Workflows
Slide 9: Gross margin negatively impacted by volume, mix, supply and cost inflation
Gross margin negatively impacted by volume, mix, supply and cost inflation Adjusted Gross Profit Bridge Q4 2021 – Q4 2022 Adj GM, % Q4 2022 58.4 34.1 40.6 48.9 (Q4 2021) (61.2) (39.5) (42.4) (52.0) Gross Margin impact +3 73 Product and Geo mix -42 -29 Supply, Absorption & Cost inflation MSEK 4,150 4
Slide 10: Financial development
Financial development Getinge │ Presentation │ Q4 Report 2022 February 1, 2023 Page 10
Slide 11: EBITA-margin negatively impacted by GP, OPEX and FX
EBITA-margin negatively impacted by GP, OPEX and FX Adjusted EBITA Bridge Q4 2021 – Q4 2022 21.6% 15.5% Margin development -3.4 pp Adj GP -406 -2.3 pp Adj OPEX 3 -0.4 pp FX -0.0 pp D&A -68 -90 -41 -194 -16 +111 MSEK Currency impact, MSEK 1,723 1,317 Q4 2021 Adj Gross Adj Selling Adj Admin Adj R&D Ot
Slide 12: Generating healthy FCF, WC days below 100 and ROIC back on trend
Generating healthy FCF, WC days below 100 and ROIC back on trend Capital efficiency a priority Positive CF in Q4 WC days below 100 Return on Invested Capital back on trend 160 140 120 1.3 14.6% 1.0 0.7 100 80 0.4 Q2 2022 0.1 0 Q4 2021 Q1 2022 Q3 2022 Q4 2022 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 2018 Q
Slide 13: Solid financial position
Solid financial position Low net debt and high margin of safety when it comes to leverage Net debt is down significantly in recent years … … and leverage is signaling financial strength 14.0 3.4x 2.6 (0,1 BSEK excl. pension liabilities) 0.4x (0.0 x excluding pension liabilities) Q1 2019 Q2 2019 Q3 2
Slide 14: Summary
Summary Getinge │ Presentation │ Q4 Report 2022 February 1, 2023 Page 14
Slide 15: Key takeaways
Key takeaways Summary Q4 2022 • Organic development on net sales and orders negatively impacted by external challenges • Margins impacted by volume, mix, supply and inflation • Healthy Free Cash Flow and financial position remains strong • External challenges remain but are expected to ease in 2023
Slide 16: Q&A
Q&A Getinge │ Presentation │ Q4 Report 2022 February 1, 2023 Page 16
Slide 17: Thank you
Thank you Getinge │ Presentation │ Q4 Report 2022 February 1, 2023 Page 17
Slide 18: Forward looking information
Forward looking information This document contains forward-looking information based on the current expectations of the Getinge’s management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectation
Slide 19: Getinge
“= Se A GETINGE PASSION FOR LIFE